Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCAR1 in a Patient With Metastatic Relapsed Alveolar Soft Part Sarcoma
NCT07104682Phase 1Active, not recruiting
- Sponsor
- University of Calgary
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GCAR1 in alveolar soft part sarcoma (ASPS), sponsored by University of Calgary. Primary endpoint: Treatment response at 12 months. Started Aug 2025; status: active, not recruiting.
02
Drugs
GCAR1
03
Conditions
alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on NCT07104682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07104682.